BREAST CANCER

Giredestrant shows significant improvement in invasive disease-free survival for early breast cancer patients, outperforming standard endocrine therapy in a pivotal trial.

Aromatase inhibitors enhance disease-free survival in HR+/HER2+ early breast cancer, outperforming SERMs without compromising overall survival, according to ALTTO trial findings.

Discover the most anticipated breast cancer abstracts at the 2025 San Antonio Symposium, featuring groundbreaking studies in HR+, HER2+, and TNBC.

Discover the most anticipated breast cancer research at SABCS 2025, featuring groundbreaking abstracts in HR+, HER2+, and TNBC. Vote now!

A novel treatment shows promise for leptomeningeal disease in breast cancer, offering hope with improved survival rates and symptom relief.

In a recent phase 2 trial, TQB2102 showed promising antitumor activity and safety as a neoadjuvant therapy for HER2-positive breast cancer.

Emerging MRD tests show promise in enhancing breast cancer treatment by improving risk stratification and clinical outcomes for patients.

Expert explores innovative strategies for managing early stage breast cancer, focusing on minimal residual disease and potential treatment adjustments.

Early-stage breast cancer patients face challenges with ctDNA detection, highlighting the need for clinical trials to improve outcomes and reduce recurrence risks.

Explore the advancements in minimal residual disease (MRD) assays, comparing tumor-informed and tumor-agnostic methods for enhanced cancer detection and treatment strategies.

Emerging research highlights the challenges and potential of ctDNA in managing minimal residual disease in breast cancer, paving the way for innovative treatment strategies.

Circulating tumor DNA (ctDNA) revolutionizes minimal residual disease detection, offering a less invasive, real-time method to monitor cancer and guide treatment.

Giredestrant shows promise as a groundbreaking treatment for early-stage breast cancer, significantly improving disease-free survival rates.

The FDA approves pertuzumab-dpzb as the first interchangeable biosimilar for HER2-positive breast cancer, enhancing treatment options and accessibility.

A coclinical trial reveals a promising triplet therapy for advanced HR+ breast cancer, highlighting the importance of genetic profiling in treatment efficacy.

A recent study reveals survival trends in metastatic breast cancer, highlighting subtype-specific treatment needs and improved outcomes for HER2-positive patients.

Study data reveal key risk factors for pneumonitis in patients with metastatic breast cancer treated with T-DXd, highlighting the need for proactive management strategies.

New trial results reveal sacituzumab govitecan shows promise for HR+/HER2– metastatic breast cancer, despite missing primary survival goals.

Camizestrant shows promising antitumor activity and tolerability when combined with CDK4/6 inhibitors in patients with advanced ER+, HER2– breast cancer.

During a live event, Sara Nunnery, MD, MSCI, and participants discussed impressions of recent data from the ASCENT-04 and ASCENT-03 trials.

Combination therapy with sacituzumab govitecan and pembrolizumab enhances quality of life and delays physical decline in metastatic triple-negative breast cancer patients.

New findings reveal significant PFS benefits of T-DXd plus pertuzumab over traditional therapies for HER2-positive advanced breast cancer patients.

Datopotamab deruxtecan significantly enhances survival rates in first-line treatment for metastatic triple-negative breast cancer, offering new hope for patients.

Trastuzumab rezetecan significantly improves progression-free survival in HER2-positive breast cancer, outperforming standard treatments in a pivotal trial.

Sacituzumab govitecan significantly improves progression-free survival in advanced triple-negative breast cancer, offering a promising alternative to chemotherapy.